OOIR: Observatory of International Research

Papers

(The median citation count of Lancet Infectious Diseases is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Transaminases and serum albumin as early predictors of severe dengue – Authors' reply	1776
Environment and infectious diseases	1312
A step forward in the journey towards hookworm vaccines	939
Surge of cutaneous leishmaniasis in Pakistan	687
Is ceftriaxone similarly effective to benzylpenicillin in neurosyphilis? – Authors' reply	642
Research in brief	606
Research in brief	600
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting	499
Attention to skin-related neglected tropical diseases	417
Infectious disease surveillance update	382
Chronicling PEPFAR's work in Africa	358
Ordinary people in extraordinary times	311
Infectious disease surveillance update	289
Promoting diversity and equity in publishing	287
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7	283
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study	278
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges	263
Adaora “Ada” Alise Adimora	261
The superiority of bivalent over monovalent booster vaccines	252
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum	247
DNDi receives Dutch funding boost	244
COVID-19 vaccination protects children and adolescents	241
Reflecting on lessons from the 2014–16 Ebola virus outbreak	237
Bold measures to accelerate malaria elimination	229
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis	229

A patient with secondary syphilis following incomplete treatment of primary infection	224
Threat of HIV and tuberculosis drug resistance after US funding cuts	220
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial	217
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial	212
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco	210
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations	208
HIV vaccine trial failure	205
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial	193
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom	191
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study	187
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic	186
Updated criteria for paediatric sepsis and septic shock	180
The next chapter for Africa's genomic initiatives	178
Transitioning to endemicity with COVID-19 research	172
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children	172
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation	172
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden	169
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines	167
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C	167
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria	166
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study	166
Measles immunity gaps and outbreak risk in a shifting landscape	165
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect	160
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review	158
The importance of understanding the infectious microenvironment	157
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blin	157
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study	156
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study	153
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis	153
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial	152
Listeria monocytogenes: a rare, deadly cause of peritonitis	152
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations	151
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1	146
Mpox in people with past infection or a complete vaccination course: a global case series	143
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2	142
History and evolution of tuberculosis and global health	141
Supporting healthcare access for refugees and migrants	141
Assessment of experimental malaria vaccine induced protection in pre-exposed populations	140
Election of Regional Director for the Western Pacific	136
The implications of mpox breakthrough infections on future vaccination strategies	135
Severe influenza: is there a role for antiviral combinations?	134
Sizing the reservoirs of malaria transmission: the contribution of school-aged children	133
Correction to Lancet Infect Dis 2021; 21: 962–74	131
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world	129
Emil Gotschlich	129
Interplay of infection and vaccination in long-term protection from COVID-19	127
Immune evasiveness of SARS-CoV-2 variants and vaccine selection	126
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis	124
Global cholera resurgence—a preventable tragedy	124
Super-spreaders: a historical review	123

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis	122
Elisabeth Presterl—always looking forward	120
WHO Pathogen X conference	120
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant	119
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?	119
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents	118
What can be learnt from the world's first national vaccination programme against gonorrhoea	117
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study	117
Research in brief	116
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study	112
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis	111
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	110
The global burden of cryptococcosis—a neglected tropical disease?	109
Effect of change in vaccine schedule on pertussis epidemiology in France: a modelling and serological study	107
Addressing the shortage of cholera vaccines	105
Allergic bronchopulmonary aspergillosis with chest pain as atypical symptoms	104
Malaria vaccine development in Mali: a step towards transmission-blocking strategies	104
Correction to Lancet Infect Dis 2023; 23: e469	103
Research in brief	102
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-0	102
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5	102
Full-dose NSAIDs at the first sign of respiratory infection?	101
Theresa Ochoa—staying on top of infectious diseases in Peru	99
Infectious disease surveillance update	99
Is combination antiviral therapy for influenza the optimal approach?	97
Curing chronic hepatitis B virus infection	96
Tuberculosis recovery in Georgia: implementing more by 24	96
Research in brief	94
Vaccine and surveillance implications of dengue underdetection	93
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86	92
RSV prevention: public health lessons from the southern hemisphere	92
High-dose primaquine reduces vivax relapses: time for change	91
COVID-19 mortality in Africa and Asia – Authors' reply	91
The response of mpox-associated inflammatory syndrome to steroid therapy	91
Patient-centred approaches for drug-resistant tuberculosis	90
Guidelines adherence as a major protective aspect to increase survival rate in patients with candidaemia in Europe	90
Correction to Lancet Infect Dis 2025; 25: e47–58	90
Research in brief	89
Serpiginous-like choroiditis in ocular tuberculosis	89
New flavours of tuberculosis treatment for children	89
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products—an update	88
We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site	87
Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention	87
Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance	86
Post-viral sequelae of COVID-19 and influenza	86
Worrying lack of funding for tuberculosis	86
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa	85
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study	85
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia	84
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-	84
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	83
Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation	82
WHO's first global infection prevention and control report	82
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study	80
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	80
Statistical concerns for meta-analysis of rare events and small sample sizes – Authors' reply	80
Twin threats: climate change and zoonoses	80
Vaccine pragmatism in the 21st century	78
Amal Saif Al-Maani—fighting antimicrobial resistance	77
Correction to Lancet Infect Dis 2021; 21: 929–38	77
Next-generation malaria subunit vaccines to reduce disease burden in African children	77
Gender and geographical representation at infectious diseases and clinical microbiology conferences	76
Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa	75
Infectious disease surveillance update	74
Child-friendly rifapentine formulation is a game changer	73
Ivermectin for malaria control in mass drug administration programmes	73
Spreading awareness on lymphatic filariasis	73
The urgent need to scale-up fungal diagnostics in Africa	73
A tale of potential mpox reinfection	73
Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7	73
Clindamycin-resistant Streptococcus pyogenes in Chinese children	72
Highlights from ECCMID 2022	72
On the frontline during the COVID-19 pandemic	71
Is the end of gonorrhoea in sight?	71
Correction to Lancet Infect Dis 2023; published online Aug 3. https://doi.org/10.1016/S1473-3099(23)00344-4	71
Correction to Lancet Infect Dis 2023; 23: e259–65	71
Sir Michael Anthony Epstein	71
Pui-Ying Iroh Tam	71
Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch	70
Research in brief	70

Moxidectin versus ivermectin for strongyloidiasis control	69
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil	69
Imprinted hybrid immunity against XBB reinfection	68
Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluste	68
Advancing integration: progress reported for skin NTDs	67
doxyPEP: a controversial new tool against STIs	67
RH5.1/Matrix-M: highlighting blood-stage malaria vaccines	67
Lessons learnt from conducting a randomised clinical trial in eumycetoma	67
Social workers and neglected tropical diseases	66
Sleeping sickness: time for dreaming	66
Human ocular thelaziosis—a zoonosis of the eye	66
Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials	66
Prevention of non-ventilator-associated hospital-acquired pneumonia in Switzerland: a type 2 hybrid effectiveness–implementation trial	66
DoxyPEP: thinking towards implementation	65
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial	65
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study	65
National case series of group A streptococcus pleural empyema in children: clinical and microbiological features	65
Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study	65
Outbreaks compound Brazil's flooding disaster	65
The origin of SARS-CoV-2 variants of concern	64
The spatiotemporal ecology of Oropouche virus across Latin America: a multidisciplinary, laboratory-based, modelling study	64
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster	64
Incidence and risk factors of tuberculosis among 420 854 household contacts of patients with tuberculosis in the 100 Million Brazilian Cohort (2004–18): a cohort study	63
A rare case of rabies-like Australian bat lyssavirus infection	63
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3	62
Hong Kong's fifth COVID-19 wave—the worst yet	62
Effectiveness of pyriproxyfen-pyrethroid and chlorfenapyr-pyrethroid long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs for malaria control in the third year post-distribution:	62
Lassa fever research priorities: towards effective medical countermeasures by the end of the decade	62
Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study	62
A step closer to elimination of meningococcal disease	62
Re-emergence of Oropouche virus in Brazil and Latin America	62
COVID-19 mortality in Africa and Asia	61
Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows	61
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial	61
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial	61
Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	60
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis	60
Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south	59
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study	59
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices	59
Lien Jih-ching	58
Experts react to SAGO's preliminary report	58
Correction to Lancet Infect Dis 2023; 23: 789	57
Monkeypox trial to begin in DR Congo	57
Infectious disease surveillance update	57
Antibody durability at 1 year after Sputnik V vaccination	56
Randomised controlled trials for mpox in endemic countries	56
Antibiotic stewardship in the real world	56
Zika vaccines: can we solve one problem without creating another one?	55
A vanquished threat or a cautionary tale?	55
Correction to Lancet Infect Dis 2022; published online Jan 25. https://doi.org/10.1016/S1473-3099(21)00586-7	54
Understanding the immunogenicity of RTS,S in infants	54
Developing the EAVE III platform for future health crises	54
Alexandra King—promoting Indigenous self-determination	54
Correction to Lancet Infect Dis 2025; 25: e11–12	54
A step forward for Plasmodium falciparum malaria transmission-blocking vaccines	53
Humanitarian crisis in Tigray amidst civil war	52
Antiblackness in the Ebola response in Sierra Leone	52
Transmissibility of SARS-CoV-2 among fully vaccinated individuals	52
Correction to Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S1473-3099(23)00731-4	52
A shared history	52
COVID-19 versus influenza: the need to align policies with COVID-19 realities	51
Mpox control strategies: using behaviour change to complement, not replace, vaccination	51
Understanding vancomycin nephrotoxicity augmented by β-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and β-lactam chemistry	51
Successful use of interferon alfa-2a for persistent parvovirus B19 infection	51
Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis	50
Reporting of deaths during cholera outbreaks: case fatality ratio and community deaths	50
Learning and confirming in publicly funded antiviral trials	50
A new formulation of praziquantel to achieve schistosomiasis elimination	50
Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions	49
Deaths of unknown cause in DR Congo	49
A new key-player for onchocerciasis elimination	48
Global measles cases up 20% in 2023	48
Azithromycin mass drug administration: balancing survival benefits and risks in children	48
Correction to Lancet Infect Dis 2025; published online Feb 13. https://doi.org/10.1016/S1473-3099(24)00749-7	48
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-base	47
Salmonella Typhimurium outbreak linked to chocolate	47
Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia	47
What is the pandemic potential of avian influenza A(H5N1)?	47
Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prosp	47
Lessons from the English primary care sentinel network's response to the COVID-19 pandemic	47
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation	47
Revisiting oral antivirals for COVID-19 in the hospital setting	47
Artificial intelligence to transform public health in Africa	46
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomi	46
The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus	46
Struggling with a new dengue epidemic in Nepal	46
Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021–22: a descriptive epidemiological study	45
Hospital admissions for group A streptococcal infections in England: current rates and historical perspective	45
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African c	45
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden	45
Research in brief	44
WHO Health For All film awards 2022	44
Growing up with polio	44
Correction to Lancet Infect Dis 2022; published online March 8. https://doi.org/10.1016/S1473-3099(21)00692-7	44